Carcinoma Overexpression and Overactivation of Akt in Thyroid Updated

Enhanced activation of Akt occurs in Cowden’s disease, an inherited syndrome of follicular thyroid, breast, colon, and skin tumors, via inactivation of its regulatory protein, PTEN. Whereas PTEN inactivation is uncommon in sporadic thyroid cancer, activation of growth factor pathways that signal through Akt is frequently identified. We hypothesized that Akt overactivation could be a common finding in sporadic thyroid cancer and might be important in thyroid cancer biology. We examined thyroid cancer cells lines and benign and malignant thyroid tissue for total Akt activation and isoform-specific Akt expression. In thyroid cancer cells, Akt 1, 2, and 3 proteins were expressed, total Akt was activated by insulin phosphatidylinositol 3 -kinase, and inhibition of phosphatidylinositol 3 -kinase reduced cell viability. In human thyroid tissue, increased levels of phosphorylated total Akt were identified in follicular but not papillary cancers compared with normal tissue. Levels of Akt 1 and 2 proteins and Akt 2 RNA were elevated only in the follicular cancers. In paired samples, Akt 1, 2, 3, and phospho-Akt levels were higher in five of six cancers, including three of three follicular cancers. These data suggest that Akt activation may play a role in the pathogenesis or progression of sporadic thyroid cancer.

[1]  G. D. Vita,et al.  Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. , 2000, Cancer research.

[2]  G. Viglietto,et al.  Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. , 2000, Cancer research.

[3]  Domenico Coppola,et al.  Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer , 2000, Oncogene.

[4]  C. Marshall,et al.  PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS , 2000, Oncogene.

[5]  J. Meinkoth,et al.  Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation , 2000, Oncogene.

[6]  M. Billaud,et al.  Transforming Ability of MEN2A-RET Requires Activation of the Phosphatidylinositol 3-Kinase/AKT Signaling Pathway* , 2000, The Journal of Biological Chemistry.

[7]  L. Schriml,et al.  Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. , 1999, Journal of the National Cancer Institute.

[8]  L. Mulligan,et al.  Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. , 1999, The American journal of pathology.

[9]  J. Wesselink,et al.  Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. , 1999, European journal of biochemistry.

[10]  V. Yong,et al.  PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. , 1999, European journal of biochemistry.

[11]  W. Liu,et al.  Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines* , 1999, The Journal of Biological Chemistry.

[12]  W. Yung,et al.  Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. , 1999, Cancer research.

[13]  J. Downward,et al.  Role of Phosphoinositide 3-Kinase in Activation of Ras and Mitogen-Activated Protein Kinase by Epidermal Growth Factor , 1999, Molecular and Cellular Biology.

[14]  H. Wu,et al.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Weigel,et al.  Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. , 1999, Biochemical and biophysical research communications.

[16]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Ritz,et al.  PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. , 1999, Human molecular genetics.

[18]  S. Filetti,et al.  Functional insulin receptors are overexpressed in thyroid tumors , 1999, Cancer.

[19]  C. Sawyers,et al.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Jen,et al.  Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors , 1998, Genes, chromosomes & cancer.

[21]  José Luis de la Pompa,et al.  Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.

[22]  P. Ladenson,et al.  Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. , 1998, Cancer.

[23]  S. Nicosia,et al.  AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. , 1998, Cancer research.

[24]  M. Santoro,et al.  Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret , 1998, Oncogene.

[25]  J. Franklyn,et al.  Fibroblast growth factors 1 and 2 and fibroblast growth factor receptor 1 are elevated in thyroid hyperplasia. , 1998, The Journal of clinical endocrinology and metabolism.

[26]  Shunhua Xing,et al.  Signal Transduction Pathways Activated by RET Oncoproteins in PC12 Pheochromocytoma Cells* , 1998, The Journal of Biological Chemistry.

[27]  J. Cheng,et al.  Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas , 1998, Molecular carcinogenesis.

[28]  J. Figge,et al.  The ret/PTC1 rearrangement is a common feature of Chernobyl-associated papillary thyroid carcinomas from Belarus. , 1998, Thyroid : official journal of the American Thyroid Association.

[29]  G. Chiappetta,et al.  RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  C. Larsson,et al.  Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. , 1997, Cancer research.

[31]  C. Eng,et al.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome , 1997, Nature Genetics.

[32]  J. Cheng,et al.  Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis , 1997, Oncogene.

[33]  M. Ivan,et al.  Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells , 1997, Oncogene.

[34]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[35]  G. Botti,et al.  Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene. , 1996, Oncogene.

[36]  P. Ladenson,et al.  Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. , 1996, Archives of internal medicine.

[37]  Y. Hayashizaki,et al.  Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. , 1996, Biochemical and biophysical research communications.

[38]  M. Ivan,et al.  Mitogenic stimulation of normal and oncogene-transformed human thyroid epithelial cells by hepatocyte growth factor , 1996, Molecular and Cellular Endocrinology.

[39]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[40]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[41]  Kunihiko Ito,et al.  Increased Activity of Insulin‐like Growth Factor‐binding Protein in Human Thyroid Papillary Cancer Tissue , 1994, Japanese journal of cancer research : Gann.

[42]  T. Ushijima,et al.  Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. , 1993, British Journal of Cancer.

[43]  M. Pierotti,et al.  Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. , 1992, Oncogene.

[44]  J. Cheng,et al.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[45]  L. Deftos,et al.  Multiple hamartoma syndrome (Cowden's disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma). , 1992, American journal of clinical pathology.

[46]  J. Fagin,et al.  Allelotype of human thyroid tumors: loss of chromosome 11q13 sequences in follicular neoplasms. , 1991, Molecular endocrinology.

[47]  S. Rubin,et al.  Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. , 1990, Molecular endocrinology.

[48]  M. Santoro,et al.  PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas , 1990, Cell.

[49]  Kunihiko Ito,et al.  Expression of insulin-like growth factor receptors in primary human thyroid neoplasms. , 1989, Acta endocrinologica.

[50]  S. Staal Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[51]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[52]  C. Eng RET proto-oncogene in the development of human cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  A. Fusco,et al.  Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis: comparison with FRTL-5 cells. , 1999, European journal of endocrinology.

[54]  J. Sagartz,et al.  Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. , 1996, Endocrinology.

[55]  J. Fagin,et al.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. , 1993, The Journal of clinical investigation.

[56]  B. Estour,et al.  Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1) , 1989, Virchows Archiv. B, Cell pathology including molecular pathology.